dopetalk
Core Topics => Psychology and Psychiatry => Topic started by: Chip on June 01, 2019, 06:29:15 AM
-
source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058719/
Psychiatric comorbidity in methamphetamine dependence
I have definitely experience Bipolar Affectife Disorder so here are some studies on what psychiatric illnesses you can expect as a tweaker.
Remember, most non-opiod using tweakers tend to be lousy people
Some excerpts (for the full text, take the source link):
Abstract
The primary aim of the present study was to assess the prevalence of psychiatric comorbidity in a large sample of methamphetamine (MA) dependent subjects using a validated structured clinical interview, without limitation to sexual orientation or participation in a treatment program.
The secondary aim was to assess whether the prevalence of psychiatric co-morbidities varied by gender. Structured Clinical Interviews (SCIDs) were administered to 189 MA-dependent subjects and lifetime prevalence of DSM-IV diagnoses was assessed. Across the sample, 28.6% had primary psychotic disorders, 23.8% of which were substance-induced; 13.2% had MA-induced delusional disorders and 11.1% had MA-induced hallucinations.
A substantial number of lifetime mood disorders were identified that were not substance induced (32.3%), whereas 14.8% had mood disorders induced by substances, and 10.6% had mood disorders induced by amphetamines. Of all participants, 26.5% had anxiety disorders and 3.7% had a substance-induced anxiety disorder, all of which were induced by MA. Male subjects reported a higher percentage of MA-induced delusions compared to female abusers.
Given the impact of MA psychosis and other drug-induced symptoms on hospitals and mental health services, the description and characterization of co-morbid psychiatric symptoms associated with MA use is of paramount importance.
Introduction
Unlike the use of cocaine, cannabis and opiates, the global problem caused by amphetamine-type stimulants appears to be growing as current data reveal that between 16 and 51 million people world-wide used such drugs illegally in 2007 (UNODC, 2009).
Adding to the international statistics are reports that admissions to publically-funded substance abuse treatment programs with methamphetamine (MA) as the primary substance increased 255% from 1997 to 2007 in the United States (SAMHSA, 2006; SAMHSA, 2008). In addition to the impairment directly associated with the disorders of MA Dependence or Abuse, psychiatric symptoms associated with MA use can cause considerable morbidity.
Published studies have reported that significant numbers of MA-dependent individuals experience symptoms severe enough to require psychiatric hospital admission, and many have attempted suicide in their lifetime (Zweben et al., 2004; Glasner-Edwards et al., 2008). Although much work has been done describing psychiatric comorbidity in cocaine-using persons (Schottenfeld et al., 1993; Ziedonis et al., 1994) and in the general drug-using population (Warner et al., 1995), less work has been carried out in MA-dependent samples (Glasner-Edwards et al., 2009, Glasner-Edwards et al., 2008, Shoptaw et al., 2003).
When co-occurring psychiatric disorders are present, they may adversely affect the response to treatment of substance use disorders (see Ries and Goldsmith, 2009 for a review). Published studies have shown that patients who had access to ongoing mental health treatment had better substance abuse outcomes compared to those who did not (Moos et al., 2002, Ouimette et al., 1998). Thus, the characterization and description of co-occurring disorders is an important first step in the treatment of co-occurring psychiatric disorders in MA abuse. Knowledge about the frequency and characteristics of co-occurring disorders may lead to improved diagnostic efficiency and accuracy. Such information may also guide clinical and programmatic planning for additional mental health services that may be required in the treatment of MA dependence